Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence
Risk stratification is an important tool in clinical decision-making, yet current approaches often fail to translate sophisticated survival analysis into actionable clinical criteria. We present a novel method for training any neural network architecture on any data modality to identify prognostical...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Article (Journal) |
| Lenguaje: | inglés |
| Publicado: |
11 May 2026
|
| In: |
npj digital medicine
Year: 2026, Volumen: 9, Pages: 1-16 |
| ISSN: | 2398-6352 |
| DOI: | 10.1038/s41746-026-02663-w |
| Acceso en línea: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41746-026-02663-w Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41746-026-02663-w 
|
| Notas de Autor: | Maximilian Ferle, Jonas Ader, Thomas Wiemers, Nora Grieb, Beatrice Berneck, Adrian Lindenmeyer, Hartmut Goldschmidt, Elias K. Mai, Uta Bertsch, Hans-Jonas Meyer, Thomas Neumuth, Markus Kreuz, Kristin Reiche & Maximilian Merz |
| Sumario: | Risk stratification is an important tool in clinical decision-making, yet current approaches often fail to translate sophisticated survival analysis into actionable clinical criteria. We present a novel method for training any neural network architecture on any data modality to identify prognostically distinct patient groups by directly optimizing for survival heterogeneity across patient clusters. We evaluate the method in simulation experiments and demonstrate its utility in practice by applying it to two distinct cancer types: analyzing laboratory parameters from multiple myeloma (MM) patients using the CoMMpass dataset and computed tomography images from non-small cell lung cancer (NSCLC) patients using the Lung1 dataset. Post-hoc explainability analyses uncover clinically meaningful features determining group assignments, which align well with established risk factors in both cases. Our findings in MM were externally validated using the GMMG-MM5 study dataset, while the NSCLC findings were validated with data from our own institution, thus lending strong weight to the method’s utility. This pan-cancer, model-agnostic approach enables the discovery of novel prognostic signatures across diverse data types while providing interpretable results that promise to complement treatment personalization and clinical decision-making in oncology and beyond. |
|---|---|
| Notas: | Gesehen am 09.07.2026 |
| Descripción Física: | Online Resource |
| ISSN: | 2398-6352 |
| DOI: | 10.1038/s41746-026-02663-w |